Adaptimmune logo Colour_white background_no strap.jpg
Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP‑A2M4 for the Treatment of Synovial Sarcoma
December 03, 2019 08:30 ET | Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics to Meet with FDA to Discuss CAP-1002 to Treat Duchenne Muscular Dystrophy
September 24, 2019 07:30 ET | Capricor Therapeutics, Inc.
LOS ANGELES, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
ExCellThera_RGB.png
ExCellThera’s lead technology, ECT-001, receives FDA Regenerative Medicine Advanced Therapy (RMAT) designation   
April 23, 2019 08:05 ET | ExCellThera
MONTREAL, April 23, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for...
2017 Capricor Final Logo v2@0.5x.png
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical Trial
November 12, 2018 07:00 ET | Capricor Therapeutics, Inc.
Focus will be on Milestones for Development and Commercialization CAP-1002 Therapy for Duchenne Muscular Dystrophy LOS ANGELES, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:...
The Alliance for Regenerative Medicine and Informa Pharma Intelligence to Host Regenerative Medicine Advanced Therapy Designation Webinar on June 13, 2018
May 29, 2018 12:09 ET | Alliance for Regenerative Medicine
WASHINGTON, D.C., May 29, 2018 (GLOBE NEWSWIRE) -- The Alliance for Regenerative Medicine (ARM) today announced it will co-host a webinar titled “RMAT Designation – Impact on the Regenerative...
Abeona Therapeutics.jpg
Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
April 23, 2018 08:15 ET | Abeona Therapeutics Inc.
First Gene Therapy Using AAV Approach Granted Regenerative Medicine Advanced Therapy Designation NEW YORK and CLEVELAND, April 23, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics...
2017 Capricor Final Logo v2@0.5x.png
Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy
February 05, 2018 11:11 ET | Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that the U.S. Food and Drug Administration (FDA) has granted CAP-1002, its lead investigational...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa
January 29, 2018 08:45 ET | Abeona Therapeutics Inc.
First gene therapy RMAT designation for Epidermolysis BullosaEnables accelerated approval path and real world data usage NEW YORK and CLEVELAND, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Abeona...